Aug 30 (Reuters) - U.S. drugmaker Otonomy Inc said on Wednesday its drug to treat Ménière’s disease, a chronic disorder of the inner ear, missed the main goal in a late-stage study.
The drug, Otividex, was tested against a placebo in 165 patients, Otonomy said.
Ménière’s typically affects one ear, causing vertigo, a persistent ringing in the ear, and ultimately, permanent loss of hearing. The disease affects about 600,000 Americans. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)